Since modulation of autophagy, especially its inhibition, is also associated with other diseases such as autoimmune and metabolic disorders, there is still debate as to which pharmacological option—induction of autophagy or inhibition of its downstream effectors (SQSTM1/NRF2, YAP)—would be the better strategy to combat liver cancer [199]. The gene discussed is NFE2L2; the disease is Other metabolic disease.